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Paroxysmal nocturnal hemoglobinuria (PNH) is a hemolytic and
pro-thrombotic disorder associated with the clonal expansion
of hematopoietic stem cells harboring somatic mutations in the
PIG-A gene.
1 Mutations in PIG-A result in a lack of surface expres-
sion of all glycosylphosphatidylinositol (GPI)-anchored proteins,
including the complement inhibitors CD55 and CD59,
2 which is
responsible for the hemolytic (and probably also the pro-thrombotic)
phenotype.
3,4 However, long-term colony-forming assays and in vivo
murine models have failed to show that PIG-A mutations are alone
sufﬁcient to drive clonal expansion.
5,6
There are two leading hypotheses to account for clonal
expansion of PIG-A-null stem cells: (i) clonal selection and (ii)
second mutations. The ﬁrst model posits that aplastic anemia---
which is epidemiologically associated with PNH---results in an
immune-mediated marrow injury that selectively spares PNH stem
cells.
7 The second hypothesis is borrowed from models of
oncogenesis and may be supported by the observation that
patients with PNH can harbor clonal cytogenetic abnormalities.
8
However, no speciﬁc gene mutations other than PIG-A have been
reported in patients with PNH---with one exception. In two
patients, a rearrangement of chromosome 12 with a break in
the 30-untranslated region of the HMGA2 gene has been reported.
9
Overexpression of an HMGA2 truncated protein recapitulates an
myeloproliferative neoplasms (MPN)-like phenotype in a murine
model and could theoretically contribute to clonal expansion in
PNH.
10
Interestingly, literature from the 1970’s has reported several
cases of PNH in association with myeloﬁbrosis and other
MPNs.
11,12 Here we report on three index cases of PNH with
myeloproliferative features harboring a JAK2
V617F mutation, which
is now understood to drive clonal expansion in many MPNs.
13
The ﬁrst case is a 51-year-old male, presenting with right hemi-
paresis and dysarthria secondary to a stroke, followed by multiple
thrombotic events, including the Budd Chiari Syndrome (BCS).
A hypercoagulable workup revealed the presence of the JAK2
V617F
mutation in the peripheral blood. Upon referral to us, a complete
Figure 1. Morphological features of the bone marrow in patients with PNH and the JAK2
V617F mutation. Patient 1: (i) hematoxilin--eosin-stained
section showing hyperplasia and mild dysplasia. (ii) Anti-factor VIII section showing increased number of megakaryocytes (stained in brown)
with mild dysplasia. (iii) Reticulin stain showing moderately increased reticulin staining (grade 2), indicative of mild ﬁbrosis. Patient 2:
(i) hematoxilin--eosin-stained section, showing hypercellularity and an increase in small hypolobated megakaryocytes. The myeloperoxidase
stain (data not shown) is strongly positive in most of the cells. (ii) Wright stain. There were no spicules present, but the aspirate is richly cellular
and demonstrates predominance of myeloid cells with an M:E ratio of B8:1. (iii) Reticulin stain showing diffuse increase in reticulin. Trichome
stain was negative. Patient 3: (i) hematoxilin--eosin-stained section, 2006, showing normocellularity; megakaryocytes were present but not
increased; (ii) repeat marrow examination in 2010, demonstrating marked distortion of the architecture by ﬁbrosis; reticulin stain was
4þ-positive at this time. (iii) peripheral smear ﬁndings in 2011 typical of a myeloproliferative syndrome: nucleated red blood cells, giant PLTs
and occasional teardrops.
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www.nature.com/bcjblood count noted an Hgb of 5g/dl, platelets (PLTs) of 492 10
9/l
and a white blood cell (WBC) 8.90 10
9/l. Bone marrow biopsy
revealed a hypercellular marrow (80--100%), dysmegakaryopoiesis,
a 4% myeloblast population and normal cytogenetics (Figure 1).
The patient later presented with an elevated lactate dehydro-
genase (LDH) and undetectable haptoglobin. Flow cytometry
Figure 2. Cellular origin of PNH and JAK2
V617F mutation. (a) To clarify the cellular origin of JAK2
V617F mutation, GPI ( ) cells and GPI (þ) cells
were isolated with ﬂuorescence-activated cell-sorting method using a FACSAria (BD Biosciences, San Jose, CA, USA). CD11b
þFLAER
  (GPI )
granulocytes, CD11b
þFLAER
þ (GPIþ) granulocytes and CD3
þFLAER
þ (GPIþ) lymphocytes were isolated from patient no.1, whereas
CD11b
þFLAER
  (GPI ) granulocytes and CD3
þFLAER
þ (GPIþ) lymphocytes were isolated from patient no. 2. Purity of sorted CD11b
þFLAER
 
(GPI ) granulocytes from patient no.1 exceeded 99%. CD11bþFLAER
þ (GPIþ) granulocytes were 83% pure. From each population, genomic
DNA was isolated using the PureLink DNA Mini Kit (Invitrogen, Carlsbad, CA, USA). The DNA tetra-primer ARMS was performed to detect the
JAK2
V617F mutation using a mutant and a speciﬁc forward primer with a common reverse primer. Presence of the mutation resulted in the
ampliﬁcation of a 203-bp DNA product; wild-type primers generated a 364-bp product. HEL and K562 cells were included as positive and
negative controls for the JAK2
V617F mutation, respectively. This analysis was non-quantitative, but demonstrated the presence and absence of
JAK2
V617F as shown (þ vs  ) in different cell populations. (b) Waterfall plot displaying clinical characteristics of JAK2
V617F-positive mutants
PNH patients (red) compared with JAK2
V617F-negative mutants (black). LDH (IU/l), % GPI (þ) granulocytes, % GPI ( ) erythrocytes, WBC,
(cells 10
9/l), hemoglobin (g/l) and PLT (cells 10
9/l) count. The percentage of GPI ( ) granulocytes, WBC and PLT are all statistically higher
(Mann--Whitney) in JAK2 mutant patients compared with controls, whereas LDH and GPI ( ) erythrocytes are not. Analyses were performed
on samples obtained from patients after provision of informed consent as per institutional protocols.
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erythrocytes were GPI ( ), conﬁrming the diagnosis of PNH, and
the patient was initiated on eculizumab. Although he has been
transfusion independent for 3 years with this therapy, he has had
multiple complications of BCS, including esophageal variceal
hemorrhage.
The second patient, a 65-year-old male, presented with
darkened urine and transfusion-dependent anemia, and was
found to have 40% PNH red cells. At that time, hematological
parameters were: WBC 6.7 10
9/l, 76.7% granulocytes Hgb 95g/l
and PLTs 580 10
9/l. His LDH was nine-fold the upper limit of
normal. Two years later, despite prophylactic anticoagulation with
coumadin, he developed a splenic infarction, prompting a
splenectomy. His WBC then rose to over 100000 10
9/l and his
PLT count to over 1000000 10
9/l, and the JAK2
V617F mutation was
identiﬁed. He developed a post-operative portal vein thrombosis,
and he was treated at that time with hydroxyurea, oral anti-
coagulation and eculizumab. Ten months later, he developed BCS
in the setting of a therapeutic international normalized ratio,
but low trough eculizumab levels; BCS completely resolved with
intravenous tissue plasminogen activator, and he was started on
aspirin, fondaparinux and hydroxyurea---and a shorter eculizumab-
dosing interval. He then developed a progressively increasing
WBC, and the marrow demonstrated hypercellularity, granulocytic
hyperplasia and moderate reticulin ﬁbrosis (Figure 1), and a 46, XY,
del (17) (p11) (18/24) karyotype. Three additional metaphases
demonstrated the del17 abnormality with a non-clonal additional
abnormality in each case. He was given decitabine, but expired
4 years after the diagnosis of PNH secondary to progressive liver
failure due to iron overload.
The third patient is a 78-year-old male with a history of prostate
cancer in 2004, treated with brachytherapy. He also had a history
of arthritis, pulmonary hypertension and cutaneous melanoma. In
2003, he was mildly anemic, and in 2006, a marrow examination
revealed hypercellularity without excess blasts. In 2009, he noticed
dark urine; the Hgb was 102g/l with 4.5% reticulocytes, PLTs
648 10
9/l, WBC 10.1 10
9/l, 77% polys, 15% lymphocytes and
7% monocytes. The LDH was 1367IU/L (normal o243), and ﬂow
cytometry demonstrated 73% CD59-negative granulocytes and
53% CD59-negative red cells. Repeat marrow examination in 2010
was notable for hypercellularity and severe ﬁbrosis (Figure 1). The
karyotype was normal (20/20), and the JAK2
V617F mutation was
identiﬁed. The patient developed transfusion-dependent anemia
not responding to eculizumab, steroids or danazol. At the time of
referral in 2011, the WBC was 12.1 10
9/l with 71% polys,
3% metamyelocytes, 2% myelocytes, 1% blasts, 10% lymphocytes,
8% monocytes, 3% basophils and 1% nucleated red blood cells;
Hgb was 79g/l and the absolute reticulocyte count was 97500/ml.
The peripheral blood smear demonstrated poikilocytosis, rare
teardrops, some giant PLTs and giant early myeloid precursors.
LDH was 1047IU/l (normal o180) and ferritin was 2908ng/ml. The
spleen was not palpable. Repeat analysis demonstrated 43%
CD59-negative red cells and 99.7% FLAER-negative, CD24-
negative granulocytes. Molecular testing again revealed the
JAK2
V617F mutation, and he was treated with eculizumab, aspirin
and fondaparinux. The patient had several bouts of pneumonia
and eventually succumbed in September 2011 to a severe
Clostridium difﬁcile infection.
A total of 26 subsequent patients (mean age, 36 years; range,
15--65) with PNH were tested for the JAK2
V617F mutation by the
DNA tetra-primer ampliﬁcation refractory mutation system
(ARMS). All patients had intravascular hemolysis and were
considered to have classic PNH. A total of 23 cases (77%) were
de novo and 7 (23%) had antecedent aplastic anemia. The
percentage of GPI ( ) granulocytes ranged from 22 to 99%
(median 71.6%) and GPI ( ) erythrocytes ranged from 0.86 to
72.3% (median 32.4%) by FLAER staining and ﬂow cytometry.
Serum LDH levels were elevated in most patients (mean 1204IU/l,
range 129--4393IU/l, normal o618IU/l). The median WBC
was 4.48 10
9/l (range, 2.44--8.90), median Hgb level was
117g/l (range, 6.4--14.0) and median PLT count was 108 10
9/l
(range, 28--648). Hepatic, cerebral or mesenteric thrombosis was
found in 6 of the 29 patients (21%), and 3 had BCS. On the basis of
the ARMS analysis, the JAK2
V617F mutation was not detected in any
of these 26 patients.
In both case 1 and 2, the molecular lesion in the PIG-A gene was
identiﬁed to be a 500-kb deletion at Xp22.2 by single-nucleotide
polymorphism array, as we have published previously.
14 To
determine the cellular origin of the JAK2
V617F mutation in these
two patients, DNA was extracted from GPI ( ) CD11b
þ
granulocytes, GPI (þ) CD11b
þ granulocytes and CD3
þ T cells
after FLAER staining and ﬂow cytometry sorting. JAK2
V617F was
selectively detected in GPI ( ) granulocytes, but not in GPI (þ)
granulocytes or T cells, clearly showing that the JAK2
V617F
mutation is not in the germline and that it co-exists within in
the PNH clone (Figure 2).
The occurrence of PNH clones in MDS and aplastic anemia is
well documented and routinely evaluated in clinical practice. This
series now documents the coexistence of PNH and JAK2
V617F-
associated MPNs in three index cases with a higher PLT count and
WBC compared with PNH patients overall (Figure 2b). Two of the
three cases were shown to harbor the JAK2
V617F mutation within
the PNH clone. In the third patient, 99% of the granulocytes were
GPI ( ), suggesting that JAK2
V617F mutation also occurred within
the PNH clone. Apart from HMGA2, this now represents the second
mutation coexisting with PNH that could explain clonal expansion.
The prevalence of PNH clones among MPN patients is unknown,
because these three index patients were ascertained by referral. In
rare patients, even before the era of ﬂow cytometry and molecular
testing, a MPN/PNH overlap syndrome was identiﬁed.
11,13,14 Of
note, no JAK2
V617F mutations were detected in 26 subsequently
screened PNH patients, suggesting that the prevalence of this
mutation is not high in classic PNH, consistent with an earlier
report.
15
On the basis of these ﬁndings, we believe that JAK2 mutation
testing should be performed on patients with PNH, who have
elevated peripheral blood counts. Considering that most patients
with PNH are mildly cytopenic (Figure 2b), this recommendation
might extend to those with blood counts towards the upper limit
of normal. Unexplained splenomegaly or a ﬁbrotic marrow would
also represent an indication for JAK2 mutation analysis. Con-
versely, patients with an MPN and signs of hemolysis should be
tested for PNH by ﬂow cytometry.
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